Jim Cramer on Olema Pharmaceuticals: “Too Risky for Me”

Too risky for me. I conscionable deliberation that astatine this stage, with this market, that 1 you could suffer excessively overmuch money. I’m precise sorry.

A laptop and a machine show show a elaborate banal marketplace method investigation chart. Photo by Jakub Zerdzicki connected Pexels

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is simply a clinical-stage biopharmaceutical institution that focuses connected processing and commercializing therapies for women’s cancers. The institution reported its Q4 2025 and full-year net connected March 16. It posted Q4 GAAP EPS of -$0.50, exceeding estimates by $0.01. Net nonaccomplishment for FY25 was $162.5 cardinal compared to $129.5 cardinal successful the anterior year.

While we admit the imaginable of OLMA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.